Ovid Therapeutics (OVID) vs. Its Rivals Head-To-Head Analysis

Ovid Therapeutics (NASDAQ:OVID – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Ovid Therapeutics to similar businesses based on the strength of its dividends, profitability, analyst recommendations, risk, institutional ownership, valuation and earnings.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Ovid Therapeutics and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ovid Therapeutics 1 0 11 0 2.83
Ovid Therapeutics Competitors 7866 13816 25856 1042 2.41

Ovid Therapeutics presently has a consensus target price of $6.12, suggesting a potential upside of 177.78%. As a group, “Pharmaceuticals” companies have a potential upside of 30.31%. Given Ovid Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Ovid Therapeutics is more favorable than its competitors.

Institutional and Insider Ownership

72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Ovid Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Ovid Therapeutics $7.25 million -$17.41 million -9.19
Ovid Therapeutics Competitors $3.54 billion $3.17 billion 556.78

Ovid Therapeutics’ competitors have higher revenue and earnings than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Ovid Therapeutics has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500. Comparatively, Ovid Therapeutics’ competitors have a beta of -0.05, meaning that their average stock price is 105% less volatile than the S&P 500.

Profitability

This table compares Ovid Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ovid Therapeutics N/A -23.38% -20.76%
Ovid Therapeutics Competitors -2,391.71% -206.07% -14.88%

Summary

Ovid Therapeutics beats its competitors on 7 of the 12 factors compared.

About Ovid Therapeutics

(Get Free Report)

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing medicines for epilepsies and other neurological disorders. Its work targets conditions with significant unmet treatment needs, including rare and difficult-to-treat seizure disorders. The company’s lead development program, OV329, is an investigational GABA aminotransferase inhibitor being studied as a potential treatment for seizures, including infantile spasms and focal-onset seizures. Ovid’s pipeline and research programs may change as clinical development progresses.

Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.